Valeant Pharma (VRX) volatility at lower end of eight month range, Sequoia Fund exited position
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... MoreRBC Highlights Next Week's Key Events for Valeant Pharma (VRX)
July 13, 2016 8:19 AM EDTRBC affirms Valeant Pharma (NYSE: VRX) at Sector Perform with a price target of $33 as the firm provides a schedule and commentary of what investors should focus on next week for the company.
RBC analyst Douglas Miehm noted:
Upcoming PDUFA dates: Oral Relistor (July 19) and latanoprostene bunod (July 21). Valeant has two PDUFA dates next week. The first, on July 19, is for Oral Relistor for the treatment of opioid-induced constipation. Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or... MoreLong-Time Valeant Pharma (VRX) Holder Sequoia Fund Exits Position
July 13, 2016 6:09 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Wednesday following news that long-time holder Sequoia Fund exited its position.
